2023 World Conference on Lung Cancer (Posters)-EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report

EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report - PDF(Abstract)

Back to course

Pdf Summary

This case report highlights the transformation of unresectable advanced non-small cell lung cancer (NSCLC) to resectable NSCLC through effective neoadjuvant therapy using aumolertinib, a novel third-generation EGFR-tyrosine kinase inhibitor. The patient, a 58-year-old female, was initially diagnosed with stage IIIC NSCLC with multiple metastases. She underwent oral icotinib treatment, which initially showed partial response, but later experienced disease progression. Further genetic testing revealed an EGFR exon 19 deletion and acquired T790M mutation, leading to the initiation of aumolertinib therapy. With aumolertinib, the patient achieved significant tumor shrinkage and downstaging to stage IB, making her eligible for surgery. A VATS right inferior lobectomy was performed, resulting in complete resection with clear margins and achieving a pathological complete response in lymph nodes. The patient then received postoperative adjuvant therapy with aumolertinib. At present, the patient is still under follow-up and has shown no evidence of recurrence or metastasis. Throughout the treatment, excellent tumor remission and favorable safety profile were observed. This case demonstrates that neoadjuvant TKI-targeted therapy can transform initially unresectable advanced NSCLC into resectable NSCLC, offering the potential for improved clinical outcomes and extended progression-free survival in patients with EGFR-mutant NSCLC.

Asset Subtitle

Cheng Chen

Meta Tag

Speaker Cheng Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

unresectable advanced non-small cell lung cancer

neoadjuvant therapy

aumolertinib

third-generation EGFR-tyrosine kinase inhibitor

stage IIIC NSCLC

metastases

icotinib treatment

EGFR exon 19 deletion

T790M mutation

VATS right inferior lobectomy